Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A placebo-controlled, double-blind Phase 1 clinical trial of SRK-015 for Spinal Muscular Atrophy

Trial Profile

A placebo-controlled, double-blind Phase 1 clinical trial of SRK-015 for Spinal Muscular Atrophy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs SRK-015 (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 08 Aug 2018 According to a Scholar Rock media release, dosing has completed in the single-ascending dose portion of the study and has advanced to the multiple-ascending dose portion of the study.
    • 31 May 2018 Status changed from planning to recruiting, as reported in a Scholar Rock media release.
    • 31 May 2018 According to the Scholar Rock media release, the company has completed dosing of the first cohort and is continuing enrolment of healthy volunteers in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top